WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 10, Issue 11, 1137-1144. Review Article ISSN 2277– 7105

# TOFACITINIB IN PATIENTS HOSPITALIZED WITH COVID-19 PNEUMONIA-A REVIEW

**Reshma Ramesan*[1] and Dr. Sruthy Renjan[2]**

[1]Sixth Year Pharm.D Intern, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Neyyattinkara, Thiruvananthapuram, Kerala, India.

[2]Clinical Pharmacist, SUT Hospital, Pattom, Thiruvananthapuram, Kerala, India.

Article Received on
11 July 2021,

Revised on 01 August 2021,
Accepted on 21 August 2021

DOI: 10.20959/wjpr202111-21549

***Corresponding Author**
**Reshma Ramesan**
Sixth Year Pharm.D Intern, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Neyyattinkara, Thiruvananthapuram, Kerala, India.

## ABSTRACT

After the arrival of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the irruption of coronavirus sickness 2019 (COVID-19) commenced across the planet. Understanding the Immunopathogenesis of COVID-19 is crucial for interrupting infectious agent infectivity and preventing aberrant immune responses before vaccination are often developed. It would have general complications and cytokine release syndrome is one among the foremost dangerous complications. many anti-cytokine medication are projected to manage this complication. However, the results of irregular trials are inconsistent and its place within the treatment of COVID-19 is however to be established.

Many consultants recommended that focus be paid to the tiny molecules that are blockers of intracellular transmitters of inflammatory signals. Janus enzyme inhibitors are the foremost promising of those molecules. Janus enzyme is connected to protein receptors and their signal is transmitted into the cell. The blockade of this enzyme ends up in a blockage in signal pathways keen about its cytokines. Therefore, Janus enzyme inhibitors occupy associate intermediate place between broad immune suppressors (glucocorticoids) and single cytokine inhibitors (tocilizumab). Recently, the results of an oversized irregular placebo-controlled trial showed that the addition of the Janus kinase inhibitor baricitinib to remdesivir improved the course of COVID-19 however had no impact on mortality. Another Janus kinase inhibitor, ruxolitinib, conjointly didn't show a big impact on mortality in a randomized placebo-controlled trial in COVID-19.

## INTRODUCTION

Coronavirus disease 2019 (Covid-19) is a viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the speedy development of vaccines, an oversized part of the planet population remains in danger for Covid-19. Therefore, effective, safe, and easy-to-administer therapies for hospitalized patients with Covid-19 area unit is necessary.[1] Severe manifestations of SARS-CoV-2 infection area unit related to exaggerated immune response driven by interleukin-6, tumor necrosis factor α, and other cytokines in a pattern is known to be a cytokine storm.[2]

COVID-19 is a viral illness caused by a unique coronavirus "severe acute respiratory syndrome coronavirus" a pair of (SARS-CoV-2), which will cause severe respiratory illness and Adult Respiratory Distress Syndrome (ARDS). Respiratory process viral load could peak atintervals of five days after onset, whereas symptoms remain still gentle. several patients quickly (within one to a pair of weeks of infection) develop dyspnoea and respiratory illness and need hospitalization for respiratory support. Preliminary clinical information from COVID-19 patients indicate that severe symptoms with SARS-CoV-2 infection are related to exaggerated immune reaction driven by lymphokines (IL)-6 IL-10, tumour necrosis factors (TNF)α, and different cytokines.[3]

The final result is progressive destruction of the alveolar epithelial tissue resulting in respiratory illness (pneumonia) or Adult Respiratory Distress Syndrome(ARDS). Moreover, the exudative part of Adult Respiratory Distress Syndrome is believed to result to inflow of myeloid cells (neutrophils and macrophages) and elevations of inflammatory cytokines, with higher levels of each IL-6 and IL-8 levels being related with high mortality. Therefore, immunomodulatory medical aid is also helpful in reducing the harmful effects such as deteriorated lungs and mitigating progressive lung injury. Tofacitinib is an inhibitor of Janus enzyme (JAKs) 1 and 3, with partial selectivity towards JAK2.

Tofacitinib suppresses pro-inflammatory communication which will be vital, pathogenetically to progression to a more severe respiratory complications like pneumonia and Adult Respiratory Distress Syndrome(ARDS) in patients with COVID-19.[2,3] The purpose of the study was to assess the safety and efficacy of tofacitinib with its pharmacologic standards and adjuvant measures in treating hospitalized patients with COVID-19 pneumonia.[1]

Tofacitinib is an orally administered selective substance of Janus enzyme (JAK) 1 and JAK3, with specific property for JAK2, that blocks intracellular transduction pathways once a cytokine is sure to its receptor. As a consequence, no cellular response is triggered, and cytokine production is indirectly suppressed. JAK inhibitors are agents that inhibit type I/II protein receptors. they're presently getting used for the treatment of some diseases, and second-generation selective JAK inhibitors are being designed and investigated.[3] Tofacitinib is a good oral JAK2/1/3 drug that was approved by the Food and Drug Administration for the treatment of Rheumatoid arthritis (RA) in 2012. Since JAK3 is limited to cytokines victimization the common γ chain family, tofacitinib will effectively block IL-2, IL-7, and IL-6. However, herpes zoster and inflammatory diseases could occur. Both low density-lipoprotein and high density lipoprotein levels increase whereas blood neutrophils get decreased.[3,4]

In a study in patients with RA, it decreased ESR and C-reactive protein levels. Tofacitinib conjointly modulates the action of interferons and interleukin-6, decreasing the discharge of cytokines by type 1 and type 17 helper T cells, that are involved within the pathologic process of the acute respiratory distress syndrome.

Tofacitinib use is related to a speedy decrease in C-reactive protein (CRP), dose dependent decreases in natural killer cells, and dose dependent increase in B cells. Depression in C-reactive protein levels continue once a pair of weeks of to facitinib termination and recommend that pharmacodynamic activity last longer than pharmacokinetic half-life. Thus, the action of tofacitinib on multiple vital pathways of the inflammatory cascade could ameliorate progressive, inflammation-driven respiratory organ injury in hospitalized patients with Covid-19.[5]

**Findings from Clinical Trials**

Participants with laboratory confirmed SARS-CoV-2 infection as determined by a positive PCR or alternative commercially offered or public health assay, who have united to participate, was screened among 72h hours after admission to the hospital to find eligibility. Eligible participants were randomised on Day 1 to the Tofacitinib and customary of care treatment cluster or the placebo and customary of care treatment cluster in a 1:1 quantitative ratio, stratified by site and required for Oxygen Participants who received treatment for up to 14 days or till discharge from the hospital, whichever is earlier. Participants were assessed daily (up to Day 28) whereas hospitalized for clinical, safety, and laboratory parameters.

Follow-up visits could occur on Day 14 and on Day 28.[6]

**Outcomes**

The primary outcome was death or respiratory failure throughout the 28 days of follow-up. Death or respiratory failure resolve to occur if participants met the standards for half- dozen (status of being hospitalized whereas receiving non-invasive ventilation or ventilation through high-flow O devices), 7 (status of being hospitalized whereas receiving invasive mechanical ventilation or ECMO), or 8 (death) on the eight-level National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale of illness severity (on a scale from 1 to 8, with higher scores indicating a worse condition).[5,7] Patients who were enrolled in the trial while they were receiving oxygen through high-flow devices (category 6) were considered to have met the criteria for the primary outcome if they presented with clinical worsening to category 7 or 8.

The prevalence of the first outcome was adjudicated by an independent clinical events classification committee, whose members were unaware of the cluster assignments.[7] The protocol and statistical analysis set up used an inverted ordinal scale, that was reversed during this report back to be per previous studies. Secondary efficacy outcomes were the cumulative incidence of death through day 28, the scores on the NIAID ordinal scale of disease severity at day 14 and at day 28, the status of being alive and not using mechanical ventilation or ECMO at day 14 and day 28, the status of being alive and not hospitalized at day 14 and day 28, cure (defined as resolution of fever and cough and no use of ventilatory or oxygen support), the duration of stay in the hospital, and the duration of stay in the intensive care unit (ICU).[7,8]

**Use of steroids along with Tofacitinb**

According to certain autopsy reports of Covid19 patients, it has been found that there is a viral cytopathic effect with intracellular small vesicles likely representing viral inclusions of unknown infectivity potential, florid lymphocytic inflammation, and diffuse capillary microthrombi in the lung parenchyma. Thus to overcome the aftereffects, certain articles discuss regarding the new treatment approach.

The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of dexamethasone (AIIa) or other corticosteroids (AIII) for the treatment of COVID-19. Patients who are receiving dexamethasone or another corticosteroid for other indications should continue therapy for their underlying conditions as directed by their health care provider.[8]

The Janus enzyme (JAK) receptors can phosphorylate and activate signal transducers and activators of transcription (STATs), that successively modulate organic phenomenon to blame for the assembly of various cytokines as lymphokine (IL)e2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-15, IL-21, and IL-22. Tofacitinib, a nonspecific JAK-STAT inhibitor, which is a potent immunomodulatory is approved as second-line therapy for several autoimmune diseases. By blocking this pathway, the production and serum levels of all these cytokines are significantly reduced. The production of other cytokines such as IL-1, IL-17, IL-18, transforming growth factor b and tumor necrosis factor is not affected by this pathway.

The fortunate treatment outcome from Dr Najjar with the usage of tofacitinib in moderate-to-severe COVID-19 respiratory illness among his patients was a milestone within the adoption of medicament medical aid. Tocilizumab (an IL-6 inhibitor) and tofacitinib were examined at the time. However, with quite 50 cytokines concerned within the inflammatory pathway, it had been believed timely, and later documented, that the protein mediate inflammatory response is central to the pneumonitis pathophysiology, it had been all over that instead of targeting one chemokine versus another (tocilizumab for IL-6 or anakinra for IL-1), tofacitinib was a lot of cheap selection because of its broad spectrum at protein production inhibition.[9]

## DISCUSSION

Cytokine release syndrome is one amongst the foremost dangerous complications of COVID-19. Despite the encouraging results from the utilization of tocilizumab in low-quality studies, recent randomized trials have created conflicting results. Thus, the place of tocilizumab, the foremost studied anti-cytokine drug, within the treatment of COVID-19 remains to be established. In this regard, it is relevant to review the impact of different groups of anticytokine medication, as well as Janus enzyme inhibitors.

Unlike monoclonal antibodies, that embrace tocilizumab, these medications are specially designed tiny molecules against Janus kinase that transmits an unhealthy signal from the membrane cytokine receptor into the cell.[10] Tofacitinib was the primary drug from this cluster to be used clinically. It had been used for the treatment of rheumatoid arthritis and inflammatory bowel diseases.[11] Among the various forms of Janus kinases, tofacitinib largely blocks JAK3, whereas, the signal from the interleukin-6 receptor is transmitted by JAK1. Therefore, the molecules with more affinity for this Janus kinase (baricitinib and ruxolitinib) were used for the treatment of cytokine release syndrome in COVID-19 before tofacitinib. However, a recent randomized placebo- controlled trial found no vital impact of

baricitinib and ruxolitinib on patient mortality. These failures created contemplate the utilization of tofacitinib, that includes a slightly different spectrum of blocked cytokine pathways. To the knowledge, no study has been revealed on its efficacy and safety in the management of COVID-19; therefore, this study was the first to be done. Unfortunately, there is no typically accepted criterion for the development of cytokine release syndrome.[12]

The best criteria could be the extent of proinflammatory cytokines, above all interleukin- 6, however these tests are expensive and aren't nevertheless offered in most clinics.[13] They used CRP as a marker for the development of this syndrome as it's the main biomarker of inflammation and could be easily determined all clinics in the world. In the study, tofacitinib reduced mortality, the rate of admission to the ICU, the degree of affected lungs, and the level of systemic inflammation.[14] In addition, it conjointly prevented the deterioration of respiratory function. It ought to be noted that during the study most patients received glucocorticoids, that may have contributed considerably to the advance of most biomarkers. However, there was no significance in the frequency of administration of those medication between the 2 groups.[15] Therefore, this distinction in mortality cannot be explained by the various frequency of usage of those medications. However, it is possible that the useful impact of tofacitinib was related to its synergistic action with glucocorticoids during the study.[15,16]

## REFERENCES

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020; 395(10229): 1054- 1062.
2. Farhad Seif, Hossein Aazami, Majid Khoshmirsafa, Monireh Kamali, Monireh Mohsenzadegan, Majid Pornour, Davood Mansouri, JAK Inhibition as a New Treatment Strategy for Patients with COVID-19, Int Arch Allergy Immunol, 2020; 181: 467–475 JAK Inhibition as a New Treatment Strategy for Patients with COVID-19, DOI: 10.1159/000508247, Int Arch Allergy Immunol, 2020; 181: 467–475.
3. Horby P, Lim WS, Emberson J, Mafham M. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med., 2021; 384: 693-704.
4. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents, 2020 Mar; 55(3): 105924.

5. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.01.31.929042.
6. Efficacy of Tocilizumab on Patients With COVID-19, https://clinicaltrials.gov/ct2/show/NCT04356937
7. Roman Maslennikov *, Vladimir Ivashkin, Ekaterina Vasilieva, Maxim Chipurik, Polina Semikova, Victoria Semenets, Tatyana Russkova, Anna Levshina, Diana Grigoriadis, Shamil Magomedov, Irina Efremova, Natiya Dzhakhaya, Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19, Pulmonary Pharmacology & Therapeutics, 2021; 69: 102039.
8. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000 Res., 2020 Jan; 9: 72.
9. Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect, 2019; 7(6): e00537.
10. C.C. Lai, Y.H. Liu, C.Y. Wang, Y.H. Wang, S.C. Hsueh, M.Y. Yen, Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths, J. Microbiol. Immunol. Infect., 2020; 53: 404– 412, https://doi.org/10.1016/j.jmii.2020.02.012.
11. Y.C. Tsai, T.F. Tsai, Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review, Therapeutic Advances in Musculoskeletal 12 (2020), https://doi.org/ 10.1177/1759720X20947296, 1759720X2094729.
12. Y. Cao, J. Wei, L. Zou, et al., Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial, J. Allergy Clin. Immunol, 2020; 146(1): 137–146, https://doi.org/10.1016/j. jaci.2020.05.019, e3.
13. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA, 2020; 324: 1330-41.
14. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med, 2021; 384: 1503-16.
15. Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P. Effect of

tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med, 2021; 181: 32-40.

16. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial, BMJ, 2021; 372. doi: https://doi.org/10.1136/bmj.n84,Cite this as: BMJ, 2021; 372: n84.